Clinical Impression

66-year-old postmenopausal female with invasive lobular carcinoma of the left breast, stage IIB (pT2N1M0). Tumor is hormone receptor-positive (ER 98%, PR 58%), HER2-negative, Ki67 11%, with MammaPrint showing Low Risk Luminal Type A. Patient underwent breast-conserving surgery with sentinel lymph node biopsy showing 1/5 positive nodes (largest 7.8mm).

Global Guidelines

1. NCCN Guidelines recommend:

• Endocrine therapy is the preferred initial treatment for hormone receptor-positive, HER2-negative disease.
• For postmenopausal women with node-positive disease, aromatase inhibitors are preferred.
• MammaPrint Low Risk result may identify patients who can avoid chemotherapy.

2. ASCO Guidelines:

• For postmenopausal women with 1–3 positive nodes and low genomic risk score, endocrine therapy alone may be appropriate.
• Aromatase inhibitors for 5–10 years is recommended for postmenopausal women.

Key Insights

1. Low genomic risk (MammaPrint Low Risk) and low Ki67 (11%) suggest favorable tumor biology.
2. Single positive node with small metastasis size (7.8mm) indicates lower risk disease.
3. Excellent hormone receptor positivity (ER 98%) predicts good response to endocrine therapy.

Clinical Trial Considerations

The RxPONDER trial demonstrated that postmenopausal women with 1–3 positive nodes and low recurrence score can safely avoid chemotherapy with endocrine therapy alone, showing no benefit from added chemotherapy.

Applied Treatment Science

1. Primary Treatment:

• Completed breast-conserving surgery with clear margins.
• Recommend whole breast radiation therapy with boost to tumor bed.

2. Systemic Therapy:

• Given postmenopausal status, low genomic risk, and single node involvement, recommend endocrine therapy alone without chemotherapy.
• Aromatase inhibitor (letrozole 2.5mg daily or anastrozole 1mg daily) for 5–10 years.
• Regular bone density monitoring during AI therapy.

Global Guidelines

According to Korean guidelines (Document #2021-150):

• Aromatase inhibitors are covered for hormone receptor positive postmenopausal breast cancer.
• Both letrozole and anastrozole are approved and funded for adjuvant use.
• Regular monitoring of FSH levels is required to confirm postmenopausal status during AI therapy.

References

1. NCCN Guidelines Version 2023 Breast Cancer.
2. Korean Breast Cancer Treatment Guidelines (2021-150).
3. Kalinsky K, et al. NEJM 2021 (RxPONDER trial).
4. MINDACT Trial (NEJM 2016) – MammaPrint validation study.